Prosensa Therapeutics BV is banking an up-front payment of £16 million (US$25.3 million) and could earn up to £412 million more from an RNA-based drug development alliance with GlaxoSmithKline plc in the X-linked neuromuscular disorder Duchenne's muscular dystrophy (DMD). (BioWorld International) Read More
